Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Chiglitazar in NASH with Elevated Triglycerides and Insulin Resistance
NCT05193916Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of chiglitazar in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Akeso, Inc. Primary endpoint: Percentage change from baseline to week 18 in liver fat content as measured by MRI-PDFF. Started Mar 2022; status: completed.
02
Drugs
chiglitazar
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05193916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193916.